Abarelix (Plenaxis™)

William P. Hogle, RN, BSN, OCN®, is a clinical manager in the Cancer Center at University of Pittsburgh Medical Center–Passavant in Pennsylvania. (Mention of specific products and opinions related to those products do not indicate or imply endorsement by the Clinical Journal of Oncology Nursing or the Oncology Nursing Society.)

Key Words: prostatic neoplasms, hormone antagonists, gonadotropins

**Drug name:** Abarelix is marketed under the trade name Plenaxis™ (Praecis Pharmaceuticals Inc., Waltham, MA).

**Classification:** Gonadotropin-releasing hormone (GNRH) antagonist.

**Action:** GNRH, also known as luteinizing hormone-releasing hormone (LHRH), binds to the anterior pituitary gonadotropic cells and stimulates the secretion of luteinizing hormone (LH) and follicle stimulating hormone (FSH). Once LH and FSH enter the circulatory system, they act on the testes, causing them to produce testosterone and dihydrotestosterone (DHT), both of which are considered androgens. LH and FSH are needed for the prostate gland to function normally and also have a role in the sustenance of malignant prostate tissue. Abarelix inhibits GNRH from binding to gonadotropinic cells, thus preventing the secretion of LH and FSH. The cascade of hormone secretion is interrupted at a very early stage, preventing the production of significant levels of the male hormones testosterone and DHT, which are known to lead to the proliferation of androgen-dependent and androgen-sensitive prostate cancer cells. Unlike currently available LHRH agonists, abarelix does not induce an initial surge of testosterone or other known androgens.

**Indications:** Abarelix is indicated for the palliative treatment of men with advanced symptomatic prostate cancer in whom LHRH agonist therapy is not appropriate or who refuse surgical castration and whom LHRH agonist therapy is not appropriate or who refuse surgical castration and should be taken into consideration. Furthermore, because patients can become refractory to abarelix, they should have their serum testosterone levels monitored periodically.

**Route and dosage:** The recommended dosage of abarelix is 100 mg administered as an IM injection into the buttock on days 1, 15, 29, and every four weeks thereafter. The cumulative risk of such a reaction increases with the duration of treatment. Other adverse reactions to abarelix that have occurred with increased frequency include hot flashes (79%), sleep disturbance (44%), pain (31%), breast enlargement (30%), breast or nipple tenderness (20%), back pain (17%), constipation (15%), peripheral edema (15%), dizziness (12%), headache (12%), upper respiratory infection (URI) (12%), and diarrhea (11%). Approximately 20% of patients who received abarelix in clinical trials experienced prolonged QT interval changes on electrocardiograms. Whether this was a direct result of drug administration, androgen deprivation therapy, or other unknown variables has not been determined.

**Adverse reactions and events:** The most significant adverse event associated with the administration of abarelix is an immediate onset systemic allergic reaction most often occurring within eight minutes of administration. The exact nature of the reported allergic reactions remains unclear. Phase IV clinical studies are under way to make this determination. The incidence rate of this type of severe allergic reaction was reported in 3.7% of patients with advanced symptomatic prostate cancer and 1.1% of all patients with prostate cancer. These immediate onset reactions have been reported to occur following any administration of abarelix, including the initial dose. The cumulative risk of such a reaction increases with the duration of treatment. Other adverse reactions to abarelix that have occurred with increased frequency include hot flashes (79%), sleep disturbance (44%), pain (31%), breast enlargement (30%), breast or nipple tenderness (20%), back pain (17%), constipation (15%), peripheral edema (15%), dizziness (12%), headache (12%), upper respiratory infection (URI) (12%), and diarrhea (11%).

**Excretion:** No detectable metabolites influence the metabolism of abarelix. Studies have indicated that the plasma clearance rate of abarelix is 50% for the first hour and 30% for the second hour after a 15 mcg/kg intramuscular (IM) injection.

**Dilution and reconstitution:** Abarelix is supplied as a single-dose, preservative-free, sterile powder that, when reconstituted with